Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 7/20 | 0.32 |
| ▸ | METTL14 | Q9HCE5 | 7/20 | 0.32 |
| ▸ | METAP2 | P50579 | 3/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | APOL1 | O14791 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27246917 | 0.87 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2METTL3METTL14 | |
| SCHEMBL27247917 | 0.87 | SMN1; SMN2 (0.38) | RAB9ANPC1SMN1; SMN2MEN1LMNA | |
| SCHEMBL30920444 | 0.87 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2METTL3METTL14 | |
| SCHEMBL30946188 | 0.87 | RAB9A (0.39) | RAB9ANPC1SMN1; SMN2MEN1LMNA | |
| SCHEMBL27383632 | 0.86 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2MEN1LMNA | |
| SCHEMBL27246821 | 0.85 | RAB9A (0.36) | RAB9ANPC1SMN1; SMN2MEN1LMNA | |
| SCHEMBL30920251 | 0.84 | SMN1; SMN2 (0.38) | RAB9ANPC1SMN1; SMN2MEN1LMNA | |
| SCHEMBL27247646 | 0.84 | SMN1; SMN2 (0.38) | RAB9ANPC1SMN1; SMN2MEN1LMNA | |
| SCHEMBL30920207 | 0.84 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27246922 | 0.84 | MTNR1A (0.42) | RAB9ANPC1SMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | RAB9A 105/4885NPC1 102/4885SMN1; SMN2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.